Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Currently, Kristy is available in the European Union and Canada markets since 2022. The approval is for the fist and only ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

The stock’s current performance reflects a positive investor response, with Biocon demonstrating promising financial results ...

Karnataka: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...

When Indian biotechnology firm Biocon and the world's biggest pharma company Pfizer announced their $350-million alliance in late October, the industry took it as another biotech pharma deal--by ...

Shares of Indian drugmaker Biocon Ltd fell about 12% on Monday after the company said its unit Biocon Biologics would buy U.S.-based Viatris Inc's biosimilars business in a transaction valued at ...

Biocon will target an initial public offering in India in late 2023. Pennsylvania-based Viatris will have the right to name on director to the Biocon board and will appoint its President, Rajiv ...

Biocon and Viatris expect to close the transaction in the second half of this year. When it happens, Viatris will have one nominee on the Biocon board of directors.

Biocon Ltd.’s shares fell the most in more than a year after the Indian drugmaker consolidated its long-standing bet on the pioneering field of complex medicines with a $3.3 billion deal to buy ...